approved$2.6B

Allogeneic cell therapy for inflammatory conditions, Ryoncil approved in Japan

approved$1.7B

Trofinetide for Rett syndrome, partnered with Acadia

phase 1 2$1.1B

Precision RNA therapeutics for genetic diseases, lead program VP-001 for retinitis pigmentosa

phase 3$782M

Copper-based radiopharmaceuticals for cancer imaging and therapy, SAR-bisPSMA lead program

approved$442M

Global specialty pharma company with SCENESSE (afamelanotide) approved by FDA and EMA for erythropoietic protoporphyria, expanding into vitiligo and xeroderma pigmentosum.

approved$203M

CelGro collagen scaffold for nerve and tendon repair; NeuraGen and TenGlide product lines

phase 2$119M

Developing Xolatryp for STEMI reperfusion injury (Phase 2) and NYR-BI03 for brain injury (Phase 1 completed). Dual cardiovascular + neuroprotection pipeline.

phase 3$167M

WiSE wireless cardiac pacing system for heart failure

phase 2$108M

Developing ISLA-101 (fenretinide) as a broad-spectrum antiviral, initially targeting dengue. Phase 2 human challenge study completed.

approved$76M

Nuclear medicine Technegas lung ventilation diagnostic

phase 1$80M

iNKT cell therapy platform for oncology

phase 2$52M

Clinical-stage company targeting extracellular matrix dysfunction with amine oxidase chemistry, focused on therapies for myelofibrosis and MDS.

preclinical$44M

Cancer diagnostics company developing EXO-NET exosome capture technology and SubB2M biomarker platform for early cancer detection.

phase 1 2$56M

FAK inhibitor AMP945 for pancreatic and ovarian cancer

preclinical$26M

Developing a simple blood test for early breast cancer detection using calcium-binding biomarkers.

preclinical$21M

Developing EmtinB, a metal-attenuating peptide for neurodegenerative diseases including Alzheimer's and motor neurone disease.

phase 1$15M

Deoxymabs (cell-penetrating antibodies) targeting intracellular DNA damage repair for cancer

phase 3$8M

Developing Presendin (repurposed drug) for idiopathic intracranial hypertension (IIH). Phase 3 trial terminated early; reassessing strategy.

approved$12M

Hyperimmune bovine colostrum antibodies for traveller's diarrhoea and NASH (Travelan, IMM-124E)

phase 3$7M

Licensed RGTA (ReGeneraTing Agent) technology for wound healing and tissue repair. CACIPLIQ20 product in Phase 3 for scars.

phase 2$18M

Sozinibercept for wet AMD, partnered with Carlyle

Biotech company at clinical stage.

Biotech company at clinical stage.

Biotech company at clinical stage.

Biotech company at clinical stage.

approved$594M

Vision-MR ablation system for cardiac catheter ablation under real-time MRI guidance

approved$349M

Cxbladder — urine-based mRNA test for bladder cancer detection, monitoring and surveillance

approved$197M

Specialty pharma focused on dermatology and women's health in the US market

approved$175M

Commercial-stage regenerative medicine company whose RECELL System delivers FDA-approved Spray-On Skin for burn wounds, full-thickness skin defects, and vitiligo repigmentation.

approved$127M

Mandibular advancement devices (MAD) for obstructive sleep apnea; sold in 28 countries

phase 2$98M

Clinical-stage biopharma developing ATH434, an oral iron chaperone targeting pathological iron accumulation in neurodegenerative diseases including multiple system atrophy.

approved$97M

Point-of-care diagnostics company. FebriDx rapid test differentiates bacterial vs viral acute respiratory infections. Pediatric validation study recruiting.

approved$18M

OncoSil phosphorus-32 brachytherapy device for unresectable pancreatic cancer; TGA/CE approved

Biotech company at clinical stage.